Apogee Therapeutics, which is developing a promising atopic dermatitis drug, saw its stock close nearly 47% higher on Monday.
Source: [MarketWatch](https://www.marketwatch.com/story/abbvie-would-gain-an-experimental-eczema-drug-by-buying-biotech-report-caf24728?mod=mw_rss_topstories)